Vaccination and immunotherapy

Section edited by: Marek Malecki

The primary objective of this section is to promote significant advances in vaccination and immunotherapy research. Of special focus are research endeavors that are entering, or have entered, “first-in-human” or phase 1 clinical trials, and areas of specific interest include: Prophylactic vaccines for HIV, HBV, HPV, HCV, Zika, Dengue, Yellow fever, Influenza, MRSA, VRSA or cancer; therapeutic vaccines for cancer; synthetic, recombinant, DNA vaccines; therapies for viral diseases; immunosuppressants; immunomodulators; therapeutics for autoimmune diseases; adverse effects and iatrogenic outcomes of vaccines and immunotherapeutics; phage, yeast, mammalian, human display based in vitro evolution; GMP production of vaccines; GMP production of antibodies and recombinant proteins; oncolytic viruses; antibody guided virotherapeutics; and viral vectors of immunotherapeutics.

  1. Research

    Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma

    Elevated expression levels of S100A6, a calcium-binding low-molecular-weight protein, were demonstrated in various malignancies. Moreover, increased serum levels of S100A6 were suggested as a novel biomarker f...

    Sven H. Loosen, Fabian Benz, Jennifer Niedeggen, Maximilian Schmeding, Florian Schüller, Alexander Koch, Mihael Vucur, Frank Tacke, Christian Trautwein, Christoph Roderburg, Ulf P. Neumann and Tom Luedde

    Clinical and Translational Medicine 2016 5:39

    Published on: 27 September 2016